Suggested remit - To appraise the clinical and cost effectiveness of eflornithine with sulindac within its marketing authorisation for treating familial adenomatous polyposis
Status Proposed
Process STA 2018
ID number 1543

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
30 October 2019 The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of eflornithine with sulindac for treating familial adenomatous polyposis ID1543. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal. On receiving information from the company that markets eflornithine plus sulindac, NICE has agreed that holding a scoping exercise at this time is not appropriate. Consequently, the scoping workshop arranged for the 04 November 2019 will be cancelled. We apologise for any inconvenience this may cause. We will send stakeholders an invitation to participate as when this scoping exercise is rescheduled. Any written comments already submitted from the first consultation will remain valid, unless you wish to withdraw your comments. If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar on (44 (0)20 7045 2239 or via email on

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance